Marre, M. K. Et Al. 2009. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). DIABETIC MEDICINE , vol.26, no.3 , 268-278.

Marre, M. K., SHAW, J., BRAENDLE, M., Bebakar, W. M. W., Kamaruddin, N. A., STRAND, J., ... ZDRAVKOVIC, M.(2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). DIABETIC MEDICINE , vol.26, no.3, 268-278.

Marre, MUSTAFA Et Al. "Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)," DIABETIC MEDICINE , vol.26, no.3, 268-278, 2009

Marre, MUSTAFA K. Et Al. "Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)." DIABETIC MEDICINE , vol.26, no.3, pp.268-278, 2009

Marre, M. K. Et Al. (2009) . "Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)." DIABETIC MEDICINE , vol.26, no.3, pp.268-278.

@article{article, author={MUSTAFA KEMAL BALCI Et Al. }, title={Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)}, journal={DIABETIC MEDICINE}, year=2009, pages={268-278} }